

1. Country: Gambia

Gambia Support for Rotavirus Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

2.	Grant number: 17-GMB-13b-X / 0 /
3.	Date of Decision Letter: 16th of December 2016
4.	Date of the Partnership Framework Agreement: 3 February 2014
5.	Programme title: New Vaccine Support (NVS), Rotavirus Routine
6.	Vaccine type: Rotavirus
7.	Requested product presentation and formulation of vaccine: Rotavirus, 2 dose(s) schedule

8. Programme duration¹²: 2013 -2017

 Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)

Agreement, if ap	piloabic		
	2013-2016	2017	Total ¹³
Programme Budget (US\$)	US\$2,704,616 ¹⁴	US\$458,500	US\$3,163,116

- 10. Vaccine introduction grant (in US\$): Not applicable
- **11. Indicative Annual Amounts:** (subject to the terms of the Partnership Framework Agreement, if applicable)¹⁵

Type of supplies to be purchased	2013-2016	2017
with Gavi funds in each year		
Number of Rotavirus vaccines		203,700
doses		
Annual Amounts (US\$)	US\$2,704,616 ¹⁶	US\$458,500

2 Chemin des Mines 1202 Geneva. Switzerland Tel. + 41 22 909 65 00 Fax + 41 22 909 65 50

¹² This is the entire duration of the Programme.

¹³ This is the total amount endorsed by Gavi for the entire duration of the Programme.

¹⁴ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.
¹⁵ This is the amount that Gavi has approved.

¹⁶ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.



- **12. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.
- 13. Self-procurement: Not applicable
- 14. Co-financing obligations: Reference code: 17-GMB-13b-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country	2017
funds in each year	
Number of vaccine doses	12,300
Number of AD syringes	
Number of re-constitution syringes	
Number of safety boxes	
Value of vaccine doses (US\$)	US\$26,940
Total co-financing payments (US\$) (including	US\$28,000
freight)	

15. Operational support for campaigns: Not applicable

	2017	2018
Grant amount (US\$)	US\$	

16. Additional reporting requirements: Not applicable

10. Additional topoliting rodal officers. Not applicable	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Country shall provide the following clarifications to Gavi*:

Not applicable

*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements

18. Other conditions: Not applicable

Signed by,

On behalf of Gavi Hind Khatib-Othman

Managing Director, Country Programmes

delate. Ko l

16th of December 2016